ÁñÁ«¹ÙÍø
Medicine & Health

Infectious Disease, Immunity & Inflammation

Coronavirus virus outbreak and coronaviruses influenza background as dangerous flu strain cases as a pandemic medical health risk concept with disease cells as a 3D render

Our vision is for a world where human health is enriched by controlling infection, enhancing immunity and managing inflammation. 

Objective

We want to better understand the way our bodies fight infection and other diseases. We investigate antimicrobials, and immune-modulating and anti-inflammatory agents in the laboratory and follow this all the way through to clinical trials. Our researchers create and work within world-class collaborative research networks, we build capacity to develop evidence-based interventions, our findings translate into clinical practice and policy, and we share new knowledge to enhance clinical care and community understanding. 

Solution

Many of our researchers are also clinicians. We work in health services and hospitals, and we conduct research through renowned centres and institutes. Our efforts focus on the response and control of emerging as well as endemic infectious diseases and health security. 

We have a strong history of rapidly and efficiently translating robust research data into clinical and policy improvements. Our approach continues to directly improve health outcomes – we revolutionise treatments so that diseases are more manageable, we advocate for healthcare access equity across all countries, and we improve the prevention of morbidities of chronic infections. 
ÁñÁ«¹ÙÍø

Impact

We contribute substantive, internationally recognised research to the evidence base that has led to revolutions in: 

  • HIV and hepatitis C treatment  
  • the prevention of morbidities of chronic infections, such as hepatitis B and human papillomavirus  
  • the diagnosis, genetics and treatment of primary immunodeficiencies 
  • understanding the immunological basis of autoimmune disease 
  • the diagnosis and treatment of antiphospholipid antibody syndrome
  • the treatment and prevention of childhood and adult allergies. 

We play a key role in providing the evidence base for the adoption of international best practice, including around COVID-19. We have an active role in determining national and international guidelines developed by the World Health Organization and other major agencies. 

Initiatives and funding

Triple I Clinical Academic Group Secondment/Exchange Program

Triple I Research supports capacity building and networking across ÁñÁ«¹ÙÍø Medicine and beyond. Placements and exchange are an opportunity to promote researcher development and training by linking partner organisations, health districts and clinical/laboratory environments.

Grants of up to $5000, supported by a detailed budget, are available for secondment and/or exchange.

For enquiries, contact Dr Sam McAllery.

Triple I Research Seed Grants

Each year, seed grants of $75,000 are available. These funds support development and nurturing of broad research collaborations across the Triple I network. Projects are expected to focus on building novel programs and solutions or transforming existing research across disparate organisational hubs into a new, harmonised entity. Applications are reviewed by an external grant review panel prior to the award being made.

For enquiries, contact Sam McAllery

Contact us

For all enquires, contact Dr Sam McAllery, Research Development Manager.

·¡:Ìýs.mcallery@unsw.edu.au